World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
39248
World Ranking
15868
National Ranking
1459

Overview

Matthew R. Sydes is affiliated with University College London in the United Kingdom and focuses primarily on medicine. Their research portfolio includes 252 publications in the broad field of medicine with notable contributions to several subfields. These subfields include Pulmonary and Respiratory Medicine, Statistics and Probability, Economics and Econometrics, Radiology, Nuclear Medicine and Imaging, as well as Public Health, Environmental and Occupational Health.

The main topics of Matthew R. Sydes' work highlight a concentration on prostate cancer and clinical trials. These topics consist of:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Ethics in Clinical Research
  • Radiopharmaceutical Chemistry and Applications
  • Meta-analysis and systematic reviews

Their recent significant publications illustrate active engagement in prostate cancer research, including studies published in leading journals such as The Lancet and European Urology. Notable papers include:

  • The Lancet Commission on prostate cancer: planning for the surge in cases, 2024, The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial, 2020, The Lancet
  • Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data, 2020, The Lancet
  • Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, 2021, JAMA Oncology

Matthew R. Sydes has collaborated frequently with several researchers, including:

  • Nicholas D. James
  • Noel W. Clarke
  • Mahesh Parmar
  • Gerhardt Attard
  • David P. Dearnaley

Their work has appeared often in specific publication venues. These journals reflect the scientific communities where their research is circulated and referenced:

  • Trials
  • Annals of Oncology
  • European Urology
  • Journal of Clinical Oncology
  • The Lancet

Best Publications

  • Practical methods for incorporating summary time-to-event data into meta-analysis

    Jayne F Tierney;Lesley A Stewart;Davina Ghersi;Sarah Burdett

  • Patient survival after D-1 and D-2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

    A Cuschieri;S Weeden;J Fielding;J Bancewicz

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.

    Gillian C. Barnett;Gillian C. Barnett;Charlotte E. Coles;Rebecca M. Elliott;Caroline Baynes

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Adaptive designs in clinical trials: why use them, and how to run and report them

    Philip Pallmann;Alun W. Bedding;Babak Choodari-Oskooei;Munyaradzi Dimairo

  • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

    Padraig Warde;Malcolm David Mason;Keyue Ding;Peter Kirkbride

  • High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

    Harry C. Schouten;Wendi Qian;Stein Kvaloy;Adolfo Porcellini

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    David P Dearnaley;David P Dearnaley;Gordana Jovic;Isabel Syndikus;Vincent Khoo

  • Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

    Nicholas David James;Melissa R. Spears;Noel W. Clarke;David P. Dearnaley

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Ian J. Lewis;Marianne A. Nooij;Jeremy Whelan;Matthew R. Sydes

  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Wanling Xie;Meredith M. Regan;Marc Buyse;Susan Halabi

  • An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study

    G. M. Mead;M. R. Sydes;J. Walewski;A. Grigg

Frequent Co-Authors

David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Malcolm David Mason
Malcolm David Mason Cardiff University
Chris Parker
Chris Parker Institute of Cancer Research
Mahesh K. B. Parmar
Mahesh K. B. Parmar University College London
Silke Gillessen
Silke Gillessen Universita della Svizzera Italiana
Gerhardt Attard
Gerhardt Attard University College London
George N. Thalmann
George N. Thalmann University of Bern
Pancras C.W. Hogendoorn
Pancras C.W. Hogendoorn Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a range of related online degrees and flexible career options. Many students consider roles beyond clinical practice, such as healthcare management or specialized nursing. For aspiring leaders, pursuing a healthcare administration degree online offers a fast-tracked route into hospital or clinic management, focusing on policy, finance, and leadership.

Nurses looking to expand their roles can benefit from flexible adn to fnp programs, bridging the gap from Associate Degree in Nursing to Family Nurse Practitioner. Those interested in holistic health may consider accredited nutrition degrees online, which prepare graduates for careers in dietetics, wellness coaching, and community health.

If you aspire to administration at the highest level, look for top cahme accredited mha programs that emphasize advanced leadership, healthcare policy, and organizational management. With online options, you can gain relevant skills to thrive in a dynamic healthcare environment alongside traditional medical studies.

Best Scientists Citing Matthew R. Sydes

Trending Scientists